Pharmacological treatment of COPD: the devil is always in the detail

Dave Singh, Peter J. Barnes, Robert Stockley, Maria Victorina Lopez Valera, Claus Vogelmeier, Alvar Agusti

Source: Eur Respir J, 51 (4) 1800263; 10.1183/13993003.00263-2018
Journal Issue: April
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Dave Singh, Peter J. Barnes, Robert Stockley, Maria Victorina Lopez Valera, Claus Vogelmeier, Alvar Agusti. Pharmacological treatment of COPD: the devil is always in the detail. Eur Respir J, 51 (4) 1800263; 10.1183/13993003.00263-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacological options for the treatment of COPD: present and future
Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy
Year: 2007

Pharmacological treatment optimisation for stable COPD: an endless story?
Source: Eur Respir J, 50 (4) 1701250; 10.1183/13993003.01250-2017
Year: 2017



Current opinion: Pharmacological approaches in asthma and COPD
Source: Breathe 2009; 6: 24-35
Year: 2009

Pharmacological treatment & current controversies in COPD
Source: ERS Course 2019 - Masterclass in airways disease 2019
Year: 2019



Diagnosis and treatment of pulmonary hypertension in COPD patients: how far should we go?
Source: International Congress 2019 – Lung vessels in COPD: it is time to take them seriously!
Year: 2019


Treatment of COPD: from pharmacological to instrumental therapies
Source: Eur Respir Rev 2009; 19: 7-23
Year: 2010


The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities)
Source: International Congress 2014 – Comorbidities
Year: 2014


LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015

Pharmacological treatment & current controversies in asthma
Source: ERS Course 2019 - Masterclass in airways disease 2019
Year: 2019


Evolving use of long-term NIV in COPD: Are we getting it right
Source: Annual Congress 2013 –Long-term NIV: COPD, sleep, obesity and outcomes
Year: 2013


Treatment of pulmonary hypertension due to COPD: can we really hope in better?
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005

Introduction: pharmacogenetic approaches in the treatment of asthma
Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology
Year: 2005

Validation of a new inhaled therapeutic algorithm for the stable COPD patient: The COPD easy treatment project
Source: International Congress 2015 – Management of COPD and other respiratory diseases in primary care
Year: 2015


Detection of previously undiagnosed COPD: A role for bronchodilator reversibility testing?
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014